Rhabdomyosarcoma-associated renal cell carcinoma: A link with constitutional TP53 mutation

Pediatric and Developmental Pathology

Volumn 14, Issue 3, 2011, Pages 248-251

  Curry, Sarah ^a   Ibrahim, Fadi ^a   Grehan, David ^a   McDermott, Michael ^a   Capra, Michael ^a   Betts, David ^a   O'Sullivan, Maureen ^a  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

Constitutional predisposition; Renal cell carcinoma; Rhabdomyosarcoma; Second malignancy

Indexed keywords

ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; CATECHOLAMINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; PROTEIN P53; SUCCIMER; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CASE REPORT; CHILD; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; EMBRYONAL RHABDOMYOSARCOMA; ESCHERICHIA COLI INFECTION; FEMALE; GENE MUTATION; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; LUNG METASTASIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSOAS MUSCLE; TUMOR VOLUME; ABDOMINAL TUMOR; COMPUTER ASSISTED RADIOTHERAPY; GENETICS; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; SECOND CANCER;

ABDOMINAL NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MUTATION; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY, CONFORMAL; RHABDOMYOSARCOMA, EMBRYONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054034556     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/10-07-0871-CR.1     Document Type: Article

References (13)

1. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009;22:S2-S23.
2. Prasad SR, Humphrey PA, Catena JR, et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006;26:1795-1806.
3. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
4. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969;43:1365-1373.
5. Trahair T, Andrews L, Cohn RJ. Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer 2007;48:345-348. (Pubitemid 46238528)
6. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002;33:310-321. (Pubitemid 34130938)
7. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002;1:97-104.
8. Forus A, Flørenes VA, Maelandsmo GM, et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Diff 1993;4:1065-1070. (Pubitemid 2020828)
9. Hedgepeth RC, Zhou M, Ross J. Rapid development of metastatic Xp11 translocation renal cell carcinoma in a girl treated for neuroblastoma. Pediatr Hematol Oncol 2009;31:602-604.
10. Barroca H, Castedo S, Vieria J, et al. Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation. Pathol Res Pract 2009;205:466-472.
11. Chen L, Malcolm AJ, Wood KM, et al. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007;6:2685-2696. (Pubitemid 350224053)
12. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006;24:476-483. (Pubitemid 46630467)
13. Felix CA, Hosler MR, Provisor D, et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996;87:4376-4381. (Pubitemid 26152278)